Should You Buy Eli Lilly Amid the Healthcare Sector's Slide? Consider This ETF Option

Eli Lilly is down 15.6% YTD, driven by its dependence on weight loss drugs, which accounted for 56% of revenue in 2025. The stock has a high P/E ratio of 40.1 but a more reasonable forward P/E of 26.1. A low-cost Vanguard ETF, the Vanguard Healthcare ETF, has a 12.6% weighting in Lilly and diversified exposure to the healthcare sector, making it a good value and a catch-all way to benefit from the industrywide boom in weight loss drugs.